Immunic Inc. Stock
Price
Target price
€0.72
€0.72
2.580%
0.018
2.580%
€8.87
14:46 / Tradegate
WKN: A2PHD4 / Symbol: IMUX / Name: Immunic / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Immunic Inc. Stock
There is an upward development for Immunic Inc. compared to yesterday, with an increase of €0.018 (2.580%).
With 19 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 8 € there is potential for a 1015.76% increase which would mean more than doubling the current price of 0.72 € for Immunic Inc..
So far the community has only identified positive things for Immunic Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Immunic Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Immunic Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Immunic Inc. | 2.580% | -13.597% | -15.375% | -49.015% | -30.861% | -84.218% | -94.822% |
| NanoViricides Inc. | -2.520% | 0.000% | -17.361% | -28.313% | -20.667% | -48.171% | -64.157% |
| Actinium Pharmaceuticals Inc. | -2.760% | 1.669% | 4.962% | -15.623% | 32.320% | -78.305% | -78.289% |
| Ocuphire Pharma Inc. | -3.260% | 4.703% | 4.383% | -4.655% | -7.748% | -54.969% | - |
Comments
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
News
Immunic (IMUX) Q2 Loss Widens 25%
Immunic (NASDAQ:IMUX), a late-stage biotechnology company focused on autoimmune and inflammatory diseases, released its second quarter 2025 results on August 7, 2025. The quarter was marked by
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
EQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis